{"id":15645,"date":"2017-06-12T14:28:27","date_gmt":"2017-06-12T13:28:27","guid":{"rendered":"http:\/\/localhost\/wp\/acse-esmart-trial\/"},"modified":"2024-07-23T12:02:55","modified_gmt":"2024-07-23T10:02:55","slug":"acse-esmart-trial","status":"publish","type":"post","link":"https:\/\/imagineformargo.org\/en\/acse-esmart-trial\/","title":{"rendered":"ACS\u00c9-ESMART TRIAL"},"content":{"rendered":"

\"RECHERCHE\"<\/strong>GIVING ACCESS TO INNOVATIVE TREATMENTS FOR CHILDREN IN RELAPSE OR WITH THERAPEUTIC FAILURE, FOR ANY TYPE OF CANCER (UNIQUE IN THE WORLD)\u00a0<\/span><\/p>\n

This trial has been co-financed with the Children without Cancer races of 2015 and 2019.<\/em><\/p>\n

ESMART – E<\/strong>uropean Proof-of-concept Therapeutic\u00a0S<\/strong>tratification Trial of\u00a0M<\/strong>olecular\u00a0A<\/strong>nomalies in\u00a0R<\/strong>elapsed of\u00a0R<\/strong>efractory\u00a0T<\/strong>umors in children<\/p>\n

 <\/p>\n

About Precision Molecular Medicine<\/strong><\/p>\n

Research projects, some of which have been funded by Imagine for Margo, have helped to better understand the biological mechanisms behind the development and progression of childhood cancers. These mechanisms, as well as the genes involved, vary from patient to patient. Each tumor is unique, has its own molecular profile, and contains specific alterations. For example, the MAPPYACTS project, also led by Dr. Birgit Geoerger, showed that 70% of patients have targetable molecular abnormalities. Unfortunately, only 30% of them could benefit from a treatment targeting these abnormalities. To address this gap, Dr. Birgit Geoerger developed a unique and innovative trial, AcS\u00e9-ESMART.<\/p>\n

 <\/p>\n

About AcS\u00e9-ESMART trial<\/strong><\/p>\n

AcS\u00e9-ESMART is a phase I and II trial, unique in the world in pediatrics, that focuses on all cancers and leukemias in children who are relapsed or treatment-resistant. The principle of this trial is to offer multiple therapeutic options with innovative treatments, usually prescribed in combination, to target molecular abnormalities frequently found in these tumors. Treatment options are offered to children based on the molecular and immunological analyses of their tumor or leukemia, mostly conducted in MAPPYACTS as well as in other European programs. This trial significantly accelerates the access of children who are relapsed or treatment-resistant to innovative treatments, regardless of their cancer type.<\/p>\n

To date, AcS\u00e9-ESMART has included 252 patients in 16 treatment arms targeting 17 molecular targets. Some of these arms are now closed due to the lack of effectiveness of the attempted therapeutic combination. However, others have opened over the years.<\/p>\n

This large-scale program is led by Gustave Roussy within the framework of the AcS\u00e9 program of the French National Cancer Institute (INCa).<\/p>\n

 <\/p>\n

Project Summary<\/strong><\/p>\n